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A B S T R A C T
Despite the considerable amount of data available on the eﬀect of donor age upon the outcomes of organ
transplantation, these still represent an underutilized resource in aging research. In this review, we have com-
piled relevant studies that analyze the eﬀect of donor age in graft and patient survival following liver, kidney,
pancreas, heart, lung and cornea transplantation, with the aim of deriving insights into possible diﬀerential
aging rates between the diﬀerent organs. Overall, older donor age is associated with worse outcomes for all the
organs studied. Nonetheless, the donor age from which the negative eﬀects upon graft or patient survival starts
to be signiﬁcant varies between organs. In kidney transplantation, this age is within the third decade of life while
the data for heart transplantation suggest a signiﬁcant eﬀect starting from donors over age 40. This threshold
was less deﬁned in liver transplantation where it ranges between 30 and 50 years. The results for the pancreas
are also suggestive of a detrimental eﬀect starting at a donor age of around 40, although these are mainly derived
from simultaneous pancreas-kidney transplantation data. In lung transplantation, a clear eﬀect was only seen for
donors over 65, with negative eﬀects of donor age upon transplantation outcomes likely beginning after age 50.
Corneal transplants appear to be less aﬀected by donor age as the majority of studies were unable to ﬁnd any
eﬀect of donor age during the ﬁrst few years posttransplantation. Overall, patterns of the eﬀect of donor age in
patient and graft survival were observed for several organ types and placed in the context of knowledge on
aging.
1. Introduction
The progressive deterioration and loss of functionality that char-
acterizes the aging process aﬀects diﬀerent systems and organs of the
body in diﬀerent ways. Through measurements at diﬀerent levels, nu-
merous microscopic, macroscopic and functional age related changes
have been robustly characterized in many diﬀerent tissues and organs
(Craig et al., 2015). In what represents a more indirect but holistic
approach, organ transplantation data give researchers the opportunity
to compare the outcomes elicited by grafts from donors of diﬀerent ages
in order to yield novel insights into the nature and pathogenesis of
organ-intrinsic aging, the eﬀect of aged organs upon the rate and pa-
thogenesis of organismal aging in young hosts, and the eﬀect of a young
host environment upon the rate and pathophysiology of aging in organs
from elderly donors. In general, the use of transplantation data to yield
insights into the nature, rate and pathophysiology of both organ and
organismal aging has remained an underutilized approach within the
broader ﬁeld of biogerontology, despite its potential to yield novel in-
sights into the dynamics of organ-intrinsic and organismal aging.
Since the beginning of clinical organ transplantation more than ﬁve
decades ago, the outcomes of diﬀerent types of transplantation have
been improving, especially with regard to short-term postoperative
outcomes, and the use of older donors has become more and more
frequent. In 2012, the number of adult transplants in the United
Kingdom alone was 2881 for kidney, 246 for pancreas, 792 for liver,
136 for heart and 179 for lung. Indeed, in the same year 35% of the
donors were 60 years old or over, compared to the 14% registered in
2003 (Johnson et al., 2014). Many clinical trials and retrospective
studies using diﬀerent databases have analyzed the eﬀect that the age of
the donor has upon postoperative outcomes for particular organs,
sometimes with conﬂicting results (Alexander and Vaughn, 1991;
Marino et al., 1995; Keith et al., 2004; Stehlik et al., 2012; Roig et al.,
2015; Bittle et al., 2013; Wakeﬁeld et al., 2015). Here, we review the
literature pertaining to the main abdominal and thoracic organs used
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for transplantation, as well as for the cornea, with the aim of providing
a more comprehensive analysis of the extent with which donor age
aﬀects patient outcomes for each speciﬁc organ and tissue included in
our analysis, and to infer possible diﬀerences in intra-organ and inter-
organ rates of aging.
2. Results
Below we review the literature on the eﬀects of donor age on the
clinical outcomes after transplantation for several organs and the
cornea, with a focus on graft and patient survivals.
2.1. Liver
Marino et al. (1995) found donor age to be an independent predictor
of graft failure following liver transplantation in the ﬁrst 90 days post
operation, as well as during the 1.12 to 2.6 years of follow-up in their
retrospective double-center study with 419 adults transplanted between
1992 and 1993. The stratiﬁcation of donor age into< 60 and
≥60 years old showed a signiﬁcant reduction in graft survival at
23 months post operation in recipients with older donors, as well as a
tendency toward the same direction when patient survival was mea-
sured. Further modeling using donor age as a continuous variable and
adjusting for additional risk factors revealed no variations in the risk of
graft failure for donors< 45 years old. They found that the risk of graft
failure began to increase progressively with the age of the donor for
donors 45 years of age and older (Marino et al., 1995). Using a larger
cohort and after stratifying the donors by age into< 20, 20–29, 30–39,
40–49 and ≥50 years old, Detre et al. analyzed patient outcomes at 6-
month following initial liver transplantation and found that, from do-
nors aged 30–39, the risk of graft failure increased progressively with
donor age. In the case of patient survival, the eﬀect was not noticed
until donors 40–49 years old, and did not increase further with the next
age group (Detre et al., 1995). In another study with a median follow-
up of three years, Feng et al. found the same progressive increase of the
risk of graft failure with donor age, starting in the group of recipients
with donors 40–49 years old as compared to those with donors
aged<40 years. In this case, however, additional stratiﬁcation of the
reference group would have been needed to know if the eﬀect starts at
an earlier donor age in this population (Feng et al., 2006).
On the other hand, in their univariate analysis, after stratifying
donors according to age at 10 year intervals Hoofnagle et al. were un-
able to ﬁnd a signiﬁcant decrease in graft survival at 3, 6, 12 and
24months for donors< 50 years of age. The multivariate analysis at
3 months, splitting donors into two groups with a cut-oﬀ age of 50,
conﬁrmed the detrimental eﬀect of older donors on graft survival but
found that this eﬀect was largely restricted to those livers assessed by
the harvesting surgeon as of poor or fair quality. When only livers that
had been assessed as being of good quality were considered, the eﬀect
of donor age lost signiﬁcance. Although no multivariate analysis was
performed using longer follow-up times, the survival curves for graft
failure showed that the ﬁrst few months posttransplantation accounted
for most of the diﬀerence seen in graft survival between old and young
donors. Compared to graft survival, donor age showed a more moderate
eﬀect on patient survival (Hoofnagle et al., 1996). Burroughs et al.
(2006) also analyzed patient survival using data of 34,664 ﬁrst adult
liver transplants from the European Liver Transplant Registry and
found that donors 41–60 years of age had worse survival outcomes at 3
and 12months than those aged≤40, but better survival outcomes than
those> 60.
The impact of donor age is also noticeable in the long term histology
of the transplanted liver. Rifai et al. found that older donor age was
associated with the presence of ductopenia and higher ﬁbrosis scores in
the biopsies from patients who were alive 10 years posttransplantation.
These authors determined that donor age< 36 years old was a pre-
dictor of normal histology in the biopsies (Rifai et al., 2004). Overall,
taking all these data into account together, liver donor age has a
measurable impact on graft and recipient survival.
2.2. Kidney
In a study involving 50,322 patients of primary deceased donor
kidney transplantation, Keith et al. found that the age of the donor was
among the three main pretransplantation factors aﬀecting long term
patient survival, along with the age of the recipient and a renal diag-
nosis of diabetes. The stratiﬁcation of donors into several age groups
revealed that the 5- and 10-year patient survivals adjusted by diﬀerent
covariates started to decrease from donors aged 36 to 40 years.
Furthermore, stratiﬁcation of the recipients into< 40, 41–54, and
≥55 year age groups revealed that, for each group, older donors were
associated with lower survival curves at 10 years posttransplantation
(Keith et al., 2004). Oppenheimer et al. studied the cases of 3365 re-
cipients with a functioning graft at one year after kidney transplanta-
tion and observed a linear increase in the risk of long term graft failure
and patient death with increasing donor age that started to become
signiﬁcant for donors 30–40 years old, as compared to the reference
group of< 20 years old. Their multivariate analysis also included the
risk of acute rejection, which did not diﬀer between the groups
(Oppenheimer et al., 2004). Laging et al. analyzed the eﬀect of donor
age using data from living and deceased donors separately and ob-
served that, in both cases, the risk of graft failure censored for death
and uncensored graft failure started to increase exponentially from
donors over 30 years old. Despite the risk curves for the two types of
donors being quasiparallel, deceased donors conferred a greater risk of
graft failure than living donors along all the age range studied. For
deceased donor transplantation, an increased risk of graft failure was
also found with pediatric donors (living donors of this age were absent)
(Laging et al., 2012).
Other studies have analyzed the impact of donor age in the out-
comes of kidney transplantation without providing additional in-
formation about the age at which this eﬀect begins to be seen.
Stratifying the donors into two groups with a cut-oﬀ age of 50, Moreso
et al. found donor age to be an independent risk factor for graft failure
for recipients who had not experienced any episodes of acute rejection.
Further analysis revealed that donor age was an independent risk factor
for graft failure due to chronic transplant nephropathy (Moreso et al.,
1999). This condition, also known as chronic allograft nephropathy
(CAN), is characterized by a progressive decline in renal function ac-
companied by histopathological changes aﬀecting the glomerular,
tubular, vascular and interstitial compartments, and is the main cause
of late graft failure following renal transplantation (Birnbaum et al.,
2009). Comparing recipients of donors 50–69 years old with those≥70,
Chavalitdhamrong et al. found transplants from older donors to in-
crease the risk of overall graft failure, death-censored graft failure and
patient death. Similar results were obtained when comparing donors
60–69 vs ≥70, but in this case the eﬀect of donor age on death-cen-
sored graft failure was not signiﬁcant (Chavalitdhamrong et al., 2008).
Along with donor age, the age of the recipient is one of the variables
commonly found to aﬀect the outcomes in organ transplantation. The
interaction between donor and recipient age has been analyzed in dif-
ferent studies for kidney transplantation with conﬂicting results. In a
secondary analysis of their data, Chavalitdhamrong et al. (2008) found
that the kidneys from donors ≥70 years old conferred a higher risk of
graft failure and patient death in recipients aged 41 to 60 than in those
aged> 60. Using data from 1269 patients, 44 of whom had a donor
older than 55, Waiser et al. (2000) found that kidneys from donors>
55 increased the risk of graft failure in young recipients (< 55) almost
two-fold but had no signiﬁcant eﬀect in older recipients (> 55). In their
univariate analysis of 201 live donor kidney transplantation recipients,
Lee et al. (2014) found that the 10-year graft survival of recipients with
donors> 10 years younger than the recipients was reduced in com-
parison to those instances in which the ages of recipient and donor were
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matched (i.e.< 10 years of diﬀerence between the recipient and their
donor).
Also in the context of interactions between donor and recipient age,
in a study with 40,289 cases of single renal transplantation, Meier-
Kriesche et al. found donor and recipient age to have an additive det-
rimental eﬀect on the risk of chronic allograft failure, for which the
authors give a deﬁnition intended to exclude causes of graft failure not
associated with CAN. This combined eﬀect in graft survival became
synergistic after the third year posttransplantation (Meier-Kriesche
et al., 2002). In another large scale study involving recipients of de-
ceased donor renal transplants, Kasiske and Snyder also studied the
interaction between donor and recipient age after stratifying both
groups into several age ranges. When the risk of graft failure in the
diﬀerent age combinations between recipients and donors was mea-
sured, no consistent deviation from the expected additive risk was
found (Kasiske and Snyder, 2002). Independently of how the age match
or mismatch between donors and recipients aﬀects survival outcomes,
the data for kidney transplantation clearly show that donor age has an
impact in recipient and graft survival.
2.3. Pancreas
Due to the relatively high risk of surgical complications and a lower
demand, the average age of donors accepted for pancreas transplanta-
tion is lower than for the other organs, resulting in a shortage of data on
patient survival curves and risk of complications for pancreas trans-
plants from old donors. This shortage of data is more marked for
Pancreas Transplantation Alone (PTA) because overall only a small
percentage of pancreas transplants are of this type. For this reason, in
the present review we have also included studies that measure pancreas
graft survival after simultaneous pancreas-kidney (SPK) and pancreas
after kidney (PAK) transplantations.
Only a few studies have addressed the eﬀect of donor age on the
outcomes of PTA independently. In a retrospective analysis of all pan-
creas transplantations performed in the United State between 2000 and
2004, Gruessner and Sutherland found reduced graft survival in pa-
tients of PTA receiving grafts from donors ≥50 years old, as compared
to those under 50, which they interpreted as being due to higher rates
of technical failure (TF) (deﬁned as early graft losses attributed to
vascular thrombosis or removal because of bleeding, anastomotic leaks,
pancreatitis, or infection) in recipients of pancreases from donors>
50 years of age. When only TF-free patients were considered, the rates
of graft survival between recipients of younger and older donors
showed no signiﬁcant diﬀerences. Similar results were found for pa-
tients of SPK transplantation (Gruessner and Sutherland, 2005). In a
more recent study, the same database was analyzed for the period of
2006–2010. When donors were stratiﬁed by age into 0–14, 15–29,
30–44 and> 44 age groups, no signiﬁcant relationship between donor
age and graft survival after PTA transplantation was observed. In pa-
tients of SPK, however, the relative risk of pancreas graft failure started
to increase with donors aged 30–44 years (Gruessner, 2011). In a dif-
ferent study, Sutherland et al. were also unable to ﬁnd a signiﬁcant
eﬀect of donor age on graft survival and TF after PTA, and observed
only a tendency toward a worse outcome in the case of SPK trans-
plantation. However, as in the case of the two previous studies, this lack
of signiﬁcance may have been due to having an inadequate sample size
(Sutherland et al., 2001).
In line with the results by Gruessner and Sutherland (2005), and
using a cohort that included SPK, PAK and PTA patients, Schenker et al.
(2008) found that the main reason for the reduced graft survival rates at
1, 5 and 10 years in recipients with older donors (≥45) was the higher
rate of early graft failure due to technical complications in this group.
The association between donor age and TF was further analyzed by
Finger et al. in a retrospective study of deceased donor pancreas
transplants performed in adults at the University of Minnesota between
1998 and 2011. They found donor age> 50 to be an independent risk
factor for graft loss within the ﬁrst 90 days posttransplantation due to
TF (Finger et al., 2013).
The detrimental eﬀect of donor age upon long-term pancreas graft
survival, independently of the early outcomes, has also been reported.
Salvalaggio et al. (2007) considered early and late pancreas graft out-
comes separately in SPK patients, and found donor age ≥45 to be an
independent risk factor for graft failure at both 90 days and 5 years after
transplantation. On the other hand, Kayler et al. (2013) found that
donors aged ≥40 reduced the 3-year pancreas graft survival after SPK
in both young recipients (< 40) and old recipients (≥40). Therefore,
while data for pancreas is more limited than for other organs, the above
data nonetheless suggest that older donors are an important risk factor
implicated in graft survival.
2.4. Heart
Diﬀerent studies have found an eﬀect of donor age in patient sur-
vival as well as in the risk of developing cardiac allograft vasculopathy
(CAV), an accelerated form of coronary artery disease developed in the
transplanted graft and one of the main causes of late mortality in heart
transplant patients. The 29th report of the International Society of
Heart and Lung Transplantation, based on transplants performed be-
tween 2001 and 2006 in 394 centers worldwide, concluded that in-
creasing donor age was associated with higher rates of mortality at 1, 5
and 15 years posttransplantation, as well as with a higher risk for the
development of CAV within 5 years posttransplantation (Stehlik et al.,
2012). Stratifying the donors into those above and below 50 years of
age, Roig et al. also found a higher incidence of CAV in recipients of
transplants from older donors at 5 and 10 years (but not at 1 year)
posttransplantation, which persisted after adjusting for diﬀerent con-
founding factors. In contrast, the higher rate of global mortality in
patients with older donors found in the multivariate analysis lost sig-
niﬁcance after adjustment for donor cause of death, donor smoking
history, recipient age, and induction and cyclosporine therapy. With
respect to acute mortality, deﬁned by the authors as deaths up to one
month posttransplantation, no diﬀerences between the two groups were
found both with and without adjustment (Roig et al., 2015). Kusch-
mann et al. also considered donor cause of death, donor smoking his-
tory, recipient age and data on the induction and cyclosporine therapy
in their 3 years follow-up study of 774 adult transplant recipients in
Germany between 2006 and 2008. Of these variables, only donor cause
of death (nontraumatic vs traumatic) and recipient age were associated
with patient survival after heart transplantation in the multiple Cox
regression analysis. This analysis also found a signiﬁcant reduction in
patient survival with increasing donor age (Kutschmann et al., 2014).
Stratifying donors into several age groups, other studies have ob-
tained a more concrete idea of the eﬀect of donor age upon medium and
long-term patient survival following heart transplantation. In a 5-year
follow-up retrospective study involving 22,960 adult transplant re-
cipients between 2000 and 2012, Weber et al. found that after adjusting
for diﬀerent donor and recipient characteristics, heart transplants from
donors 40–49 years of age were associated with a slightly increased risk
of mortality with respect to those aged 18–39, and that this diﬀerence
increased progressively in each successive age group (50–55 and>55)
(Weber et al., 2014). This is consistent with 40–49 years of age marking
the beginning of a curve of decreasing patient survival, but further
stratiﬁcation of the reference group would have been needed to de-
termine whether the eﬀect starts any earlier. A similar result was ob-
tained by Gupta et al. who, using a cut-point analysis, concluded that
transplants from donors aged 40 years or older were associated with
poorer survival rates independently of the other risk factors found in
their single-center study involving 667 recipients (Gupta et al., 2004).
On the other hand, Nagji et al. analyzed the eﬀect of diﬀerent donor
ages on the onset of CAV and found that, starting from donors
30–39 years old, the risk of developing this pathology increased pro-
gressively with the age of the donor. A further analysis comparing the
J.C. Dayoub et al. Experimental Gerontology 110 (2018) 230–240
232
eﬀect of transplants from donors under 20 years old with those from
donors aged 50 or over upon diﬀerent recipient age groups (18–29.9,
30–39.9, 40–49.9 and ≥50 years old) revealed that transplants from
older donors were associated with a higher risk of developing CAV in all
the recipient age intervals considered (Nagji et al., 2010). As seen in
other organs, the data presented here also show an evident detrimental
eﬀect of donor age in patient outcomes following heart transplantation.
2.5. Lung
Baldwin et al. studied the eﬀect of donor age on graft survival using
the records of 8860 cases of adult lung transplantation performed be-
tween 2005 and 2011, as provided by the American Organ Procurement
and Transplantation Network (OPTN). When treating donor age as a
continuous variable, a slight increase in the risk of graft failure at 1 year
was observed with the use of donors younger than 18 years which, after
declining to a minimum between donors aged 30 and 50 years, in-
creased with donor age progressively throughout the rest of the age
range studied. Further stratiﬁcation of donor age gave similar results:
recipients of donors< 18 presented an increased risk of 1-year graft
failure with respect to the reference group (18–29 years), but revealed
no signiﬁcant diﬀerences in this outcome for transplants from donors
aged between 18 and 64. Donors ≥65 exerted a strong negative eﬀect
on graft survival, with a relative risk of graft failure at 1 year that
reached more than two-fold that of transplant recipients from the re-
ference group. This eﬀect of the oldest donors, however, lost sig-
niﬁcance when it was measured at 5 years posttransplantation in re-
cipients who had not experienced graft failure during the ﬁrst year
posttransplantation, 67 of whom had a donor 65 years old or over
(Baldwin et al., 2013). Using the same database for the period of
2000–2009, Bittle et al. obtained similar results when analyzing the
eﬀect of donor age in patient survival. While the risk of mortality at
30 days did not diﬀer signiﬁcantly between the diﬀerent age groups
(18–34, 35–54, 55–64 and ≥65), a strong negative eﬀect of donors
≥65 at 1 and 3 years posttransplantation, which lost signiﬁcance when
measured at 5 years posttransplantation, was found in their multi-
variable logistic regression analysis. On the other hand, their univariate
analysis showed no diﬀerences between groups in the incidence of
bronchiolitis obliterans syndrome (BOS), the most common form of
chronic lung allograft dysfunction and the main limitation associated
with long-term patient survival following lung transplantation (Bittle
et al., 2013). The eﬀect of donor age upon the risk of developing BOS
was studied in more detail by Hennessy et al. who, also using the OPTN
database, examined the association between diﬀerent donor factors and
the onset of this condition in 6991 recipients with relevant follow-up
data transplanted between 1987 and 2008. Stratifying the donors by
age into<60 and ≥60 groups, these authors found transplants from
older donors to be an independent risk factor for the development of
BOS during the ﬁrst 5 years posttransplantation (Hennessy et al., 2010).
Using smaller cohorts and stratifying recipients into two groups
according to donor age, three other studies also examined the eﬀect of
donor age upon patient survival following lung transplantation. In their
univariate analysis and using a cut-oﬀ age of 50 and 55 years, respec-
tively, Fischer et al. and Shigemura et al. did not ﬁnd a signiﬁcant eﬀect
of donor age in patient survival measured at diﬀerent points between
1month and 5 years posttransplantation, while De Perrot et al. found
only a minor tendency to increased mortality at 30 days and 10 years
posttransplantation for transplants from donors aged 60 years or older
(Fischer et al., 2005; Shigemura et al., 2014; De Perrot et al., 2007).
Therefore, data relating to the eﬀect of donor age upon lung transplant
recipient survival is somewhat conﬂicting, although an eﬀect of donor
age upon transplant recipient and graft survival from larger studies is
clear.
2.6. Cornea (penetrating keratoplasty)
In a prospective clinical trial, the Corneal Donor Study (CDS) ex-
amined the eﬀect of donor age upon graft survival in 1090 patients
undergoing penetrating keratoplasty (PK) in diﬀerent centers of the
United States between 2000 and 2002 for an endothelial condition
considered to be at moderate risk for graft failure (deﬁned in the study
as a regraft or a cloudy cornea that was suﬃciently opaque to com-
promise vision for a minimum of three consecutive months). At ﬁve
years posttransplantation no signiﬁcant eﬀect of donor age on graft
survival was found for all the age range studied when donor age was
analyzed as a continuous variable. The stratiﬁcation of the donors into
several age groups revealed similar survival curves across all groups,
and only a slightly higher survival curve in the youngest group
(12–30 years) (Gal et al., 2008). At 10 years posttransplantation, this
eﬀect became more marked and a second inﬂection point appeared
after the ﬁfth year posttransplantation toward the end of the age range,
where the survival rate for the oldest group (71–75) reached a
minimum. These apparent diﬀerences were supported by the associa-
tion between donor age and graft survival found in the analysis at
10 years posttransplantaion with donor age treated as a continuous
variable (Mannis et al., 2013). In parallel to the corneal donor study
and using the same cohort, the Specular Microscopy Ancillary Study
(SMAS) evaluated the eﬀect of donor age on corneal endothelial cell
loss posttransplantation, in which the recipients were stratiﬁed into
those with transplants from donors 12–65 years old and those with
transplants from donors aged 66–75 years. Apart from a substantial
decrease in endothelial cell density (ECD) over the time in both groups,
the authors found a slight but signiﬁcant positive association between
donor age and endothelial cell loss at 5 and at 10 years post-
transplantation independent of the level of ECD present at the moment
of transplantation (Lass et al., 2008; Lass et al., 2013). This ﬁnding is
consistent with the decrease in ECD with age found in the corneas of
healthy individuals in other studies (Sanchis-Gimeno et al., 2005;
Armitage et al., 2014).
Other groups have also studied the eﬀect of donor age upon graft
survival following penetrating keratoplasty (PK). Wakeﬁeld et al. ana-
lyzed 9415 cases of PK performed in the UK between 1999 and 2012
and, after stratiﬁcation of donors by age into 0–60, 61–75 and
76–90 year old cohorts and adjusting for diﬀerent potential con-
founding factors, no signiﬁcant diﬀerence in the rates of endothelial
failure at 5 years posttransplantation were found between recipients of
transplants from diﬀerent donor age groups (Wakeﬁeld et al., 2015).
Using the Australian Corneal Graft Register (ACGR) database for the
period 1985–1996, Williams et al. analyzed data from 7741 patients
with transplants from donors aged from<1 year to> 90 years. In their
analysis, stratifying donors by age in 10 years intervals, the authors
were unable to ﬁnd any signiﬁcant eﬀect of donor age upon graft sur-
vival up to 10 years post operation (Williams et al., 1997). However, in
the 2015 ACGR report, based upon the outcomes of transplants per-
formed between 2000 and 2014, a signiﬁcant eﬀect of donor age on
graft survival following penetrating keratoplasty was found. The mul-
tivariate analysis showed that graft survival started to decrease in
transplants from donors aged over 60. Although the report does not
specify exactly when the diﬀerences between transplants from younger
and older donors start to become signiﬁcant, the overall results indicate
that graft survival rates were equivalent in all groups during the ﬁrst
year and the diﬀerences between graft survival in transplants from
older and younger donors increase progressively as they are reported
for 3, 6 and 9 years posttransplantation (Williams et al., 2015). As such,
the data suggest some eﬀects of donor age upon graft survival in cornea
transplantation, but further studies are warranted in order to reach
stronger conclusions.
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3. Discussion
The data available from organ transplantation show that increasing
donor age negatively aﬀects patient and graft survival in all organs
studied where these two outcomes were measured (no data for graft
survival in heart transplantation are presented here), as well as the risk
of some other postoperative complications. Older donor age was also
associated with a higher risk of graft failure following cornea trans-
plantation. As one would expect from the normal process of aging, this
eﬀect of donor age upon survival outcomes is in general progressive, in
the sense that it starts at a certain donor age and increases in tandem
with increasing donor age. An exception to this pattern is the aug-
mented risk of graft failure in transplants from pediatric donors that the
studies by Baldwin et al. (2013) and Laging et al. (2012) found in lung
and kidney transplantation data, respectively. Apart from these results,
some studies in kidney transplantation have reported a relatively po-
sitive eﬀect in patient or graft survival outcomes derived from age
matching between donors and recipient (Chavalitdhamrong et al.,
2008; Waiser et al., 2000; Lee et al., 2014). However, the number of
recipients receiving grafts from old donors in these studies was not high
enough to provide solid evidence of this. Even though an eﬀect in this
sense cannot be excluded, the results of diﬀerent large-scale studies in
kidney and other organ transplants suggest that, at least in the case of
adult to adult transplantation, increasing donor age is associated with
worse outcomes in all recipient age groups (Keith et al., 2004; Meier-
Kriesche et al., 2002; Kasiske and Snyder, 2002; Nagji et al., 2010).
It is notable that some studies do not ﬁnd any eﬀect of donor age
upon short-term postoperative outcomes despite ﬁnding this eﬀect in
the longer term. This could be due to any eﬀects of donor age upon
short-term patient and graft survival outcomes being masked by the
comparatively greater eﬀect of acute rejection and complications de-
rived from surgical trauma upon short-term patient and graft survival
outcomes. Other studies, however, do report a negative eﬀect of donor
age upon short-term patient and graft survival outcomes. Given the
particularity of this early stage and the variability of results between
studies, we have focused our comparisons upon studies analyzing
longer-term outcomes (i.e. 6 months or more following transplanta-
tion). From an aging perspective, long-term studies are also more ap-
propriate to study organ deterioration during aging.
The studies included in this review show that for each organ type,
more or less deﬁned patterns can be seen with respect to the age of the
donor at which its negative eﬀect on patient and graft survival out-
comes becomes noticeable. In the case of the liver, three of the studies
measuring graft survival via multivariate analysis in the short-medium
term found this age to be between the third and the fourth decade of life
(Marino et al., 1995; Detre et al., 1995; Feng et al., 2006). The results
found for patient survival are consistent with these ﬁndings despite the
fact that the intervals of donor age used to stratify the donors by Bur-
roughs et al. were too wide to deﬁne this age (Marino et al., 1995; Detre
et al., 1995; Burroughs et al., 2006). The study by Hoofnagle et al.
(1996), however, did not ﬁnd any signiﬁcant eﬀect on graft survival in
its univariate analysis until donors aged< 50–59 years. This is sub-
stantially higher than the donor age at which negative eﬀects on graft
survival become signiﬁcant found by the other studies for liver trans-
plantation included here (Marino et al., 1995; Detre et al., 1995; Feng
et al., 2006), but because this analysis did not take into account possible
confounding factors, this ﬁnding is less conclusive. It must be noted that
the multivariate analysis showed that the poorer graft survival at
3months posttransplantation conferred by older donors was restricted
to those livers assessed by the harvesting surgeon as of poor or fair
quality (Hoofnagle et al., 1996). It remains unknown, however, if this
association would have been maintained in the longer term and also the
eﬀect that this variable would have had in the results of the other liver
transplant studies reviewed if they had included it in their analyses.
The results observed for kidney are more homogeneous than those
for liver. As seen in Table 1, four independent results (three using
deceased donors and one using living donors) in three diﬀerent studies
found that donor age begins to have a signiﬁcant negative eﬀect on
patient and graft survival at around 30–40 years (Laging et al., 2012;
Keith et al., 2004; Oppenheimer et al., 2004). The study by Laging et al.
(2012) also found improved patient and graft survival outcomes when
using transplants obtained from living rather than deceased donors, a
result reported in other studies and that, according to a study by
Roodnat et al. (2003), could be explained in part, but not exclusively,
by the longer periods of cold ischemia time used with deceased donors.
Two additional studies comparing only two donor age groups con-
ﬁrmed the negative eﬀect of donor age upon patient and graft survival,
which was noticeable even when comparing donors 60–69 with do-
nors> 70 (Chavalitdhamrong et al., 2008; Moreso et al., 1999).
For pancreas transplantation, the only study that stratiﬁed donors
into several age groups found those aged 30–44 to be the ﬁrst that
exerted a negative eﬀect in graft survival (Gruessner, 2011). In addi-
tion, from the other studies it is apparent that when stratifying donors
into two groups with a cut-oﬀ age of between 40 and 50 years, re-
cipients of transplants from older donors have a higher risk of early
graft loss due to technical failure (Gruessner and Sutherland, 2005;
Schenker et al., 2008; Finger et al., 2013), a risk that in the study by
Salvalaggio et al. (2007) is noticeable in medium to long term graft
survival as well. These results have to be considered with caution be-
cause they are mainly obtained using data from SPK transplantation, a
type of transplantation in which patients have also received a new
kidney. This introduces a confounding variable into these results be-
cause SPK transplantation graft survival curves are known to be sub-
stantially higher than those observed in PTA. While one study mea-
suring graft survival in PTA independently showed a similar result to
that in SPK, additional studies in PTA patient and graft survival would
be necessary to obtain any conﬁdent determination as to whether donor
age exerts a similar relative eﬀect in both types, as well as to arrive at a
conﬁdent determination of how donor age aﬀects pancreatic graft
survival.
In heart transplantation, two studies suggest that medium-long term
patient survival starts to signiﬁcantly decrease in recipients of trans-
plants from donors aged over 40 (Weber et al., 2014; Gupta et al.,
2004), which is consistent with studies measuring the threshold for
onset of CAV (30–39 years) (Nagji et al., 2010). The rest of the studies
we reviewed conﬁrm the negative eﬀect of donor age in patient survival
found by the above two analyses, except for that of Roig et al. (2015), in
which the increased risk of death associated with the use of transplants
from older donors (i.e. < 50 vs ≥50 year old donors) found in the
multivariate analysis lost signiﬁcance after adjusting for donor cause of
death, donor smoking history, recipient age, and induction and cy-
closporine therapy. This contrasts with the results obtained by
Kutschmann et al. (2014), where, of those potential confounders, only
donor cause of death and recipient age were found to have an eﬀect on
patient survival, and donor age exerted a negative eﬀect in patient
survival that was independent of the age of the recipient. Also, it is
remarkable that Roig et al. found a signiﬁcant negative eﬀect of donor
age on the risk of developing CAV, which is a cause of mortality itself.
Two large scale studies show that donors over 65 strongly aﬀect
medium term patient and graft survival outcomes, respectively, in the
context of lung transplantation, an eﬀect that for graft survival starts to
be noticeable from donors over 50 (Baldwin et al., 2013; Bittle et al.,
2013). The lack of signiﬁcance found in the rest of studies we reviewed
for lung transplants, which used smaller cohorts and as such obtained
less conclusive results, could also be consistent with these ﬁndings
(Fischer et al., 2005; Shigemura et al., 2014; De Perrot et al., 2007).
Cornea transplantation outcomes appear to be much less aﬀected by
the age of the donor. The data reviewed here show that, with the
possible exception of the 2015 ACGR report (Williams et al., 2015),
none of the studies found a signiﬁcant eﬀect of donor age upon graft
survival ﬁve years after PK, with donor ages ranging from<10 to>90
(Gal et al., 2008; Mannis et al., 2013; Wakeﬁeld et al., 2015; Williams
J.C. Dayoub et al. Experimental Gerontology 110 (2018) 230–240
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et al., 1997). More evidence exists in the long term regarding the eﬀect
of donor age in graft survival. This lower eﬀect of the age of the donor
upon graft survival seems reasonable given the relatively simple
structure of the cornea with respect to other commonly-transplanted
organs and its lack of vasculature. The vascular system undergoes
structural and functional changes with age that impair its function at
diﬀerent levels (Scioli et al., 2014; Ungvari et al., 2010), and as such it
is logical to think that age-related changes in vasculature and micro-
vasculature of the diﬀerent organs must be a signiﬁcant factor con-
tributing to their age related dysfunction. The lack of vasculature of the
cornea is also in part responsible for its known immune privilege, which
makes the corneal grafts much less prone to rejection than other organs
used for transplantation. In fact, in contrast to the necessary use of
systemic immunosuppressants in recipients of any of the vascularized
organs, topical administration of corticosteroids constitutes the im-
munosuppressive treatment for the patients of corneal transplantation
(Niederkorn and Larkin, 2010).
In addition to patient and graft survival, some authors have studied
the eﬀect of donor age on the particular forms of chronic allograft
dysfunction (CAD) in kidney, heart and lung transplantation (that is,
CAN, CAV and BOS respectively), showing that older donor age is a risk
factor for the development of each of these conditions (Moreso et al.,
1999; Meier-Kriesche et al., 2002; Stehlik et al., 2012; Roig et al., 2015;
Nagji et al., 2010; Hennessy et al., 2010). CAD, sometimes also referred
to as chronic rejection, is a term used in solid organ transplantation to
refer to a progressive decline of functionality of the transplanted organ
that is accompanied by characteristic histopathological changes in it
and that ultimately leads to graft failure since there is not an eﬀective
treatment for it at the moment. In heart and kidney transplantation, the
eﬀect of donor age upon CAV and CAN is clearly seen, along with
consistently high incidences of these two conditions in the recipients,
which suggests that the eﬀect of donor age upon medium and long term
graft and patient survival seen in heart and kidney transplantation
could be due in a substantial part to its eﬀect on CAV and CAN re-
spectively. In lung transplantation, the similar incidence of BOS in
diﬀerent age groups found by Bittle et al., as well as the lack of sig-
niﬁcant eﬀect seen by these authors and by Baldwin et al. of donor age
upon patient and graft survival at 5 years posttransplantation, where
the deaths due to BOS have been estimated to be> 25% of all cases
(Yusen et al., 2015), suggest that the eﬀect of donor age upon the risk of
developing BOS is more moderate. Liver and pancreas transplantation
patients can also present CAD, but in these cases less is known about the
extent of the eﬀect of donor age.
Although each organ type presents a particular set of histopatho-
logical manifestations associated with CAD, there are some common
features, such as interstitial ﬁbrosis and ﬁbrointimal hyperplasia of
arteries, that aﬀect all of them to some degree (Demetris et al., 1998).
Etiologically, alloimmune-mediated processes are known to be the main
causative factor leading to CAD, but it is known that non-im-
munological factors, such as hypertension, hyperlipidemia or post-
ischemic reperfusion injury, can also contribute to its development,
probably at least in part through diﬀerent insults to the allograft that
further exacerbate the innate immune response (Land, 2013).
Little is known about the mechanisms through which donor age
inﬂuences the development of CAD. A possibility suggested by other
authors in the case of heart transplantation is that older grafts could
already have subclinical coronary disease at the time of transplantation,
which could result in the earlier onset of CAV (Nagji et al., 2010). A
more dysfunctional endothelium in the older graft could be a main
causative factor because endothelial dysfunction, which is known to
increase with age, leads to a more pro-inﬂammatory endothelium that
favors atherosclerotic processes (Donato et al., 2015; Mudau et al.,
2012). The unequivocal eﬀect of donor age on CAD in heart and kidney
transplantation, where the obliterative arteriopathy is of particular
importance, compared to the less clear eﬀect of donor age in this re-
spect in lung transplantation, where the vascular disease is considered
less relevant, strengthens this idea. Some studies with patients and
animal models of kidney transplantation have also reported a stronger
immune response in recipients with older donors during the early
postoperative period which, through an elevated occurrence of acute
rejections episodes, could increase the risk of CAD in the longer term
(de Fijter et al., 2001; Reutzel-Selke et al., 2007).
3.1. Caveats and limitations
Although from the studies available in the scientiﬁc literature it
seems evident that increasing donor age has a negative eﬀect upon
patient and graft survival outcomes in organ transplantation, at-
tempting to obtain a more detailed picture of the extent of this eﬀect in
diﬀerent organs is a challenging task. One limitation is the high
variability to which this model is exposed. In addition to characteristics
of donors with a potential confounding eﬀect (e.g., cigarette usage,
history of diabetes, cause of death and body mass index), intraoperative
characteristics aﬀecting grafts from young and old donors in distinct
manners or bias in the assignment to recipients of these organs can
distort the perceived eﬀect of donor age. Hoofnagle et al. (1996), for
example, found that the duration of the operation for the procurement
of livers in older donors was signiﬁcantly higher than in young donors.
Also, some studies report a tendency to assign older grafts to older
recipients, which would overestimate the negative eﬀect of donor age
in those studies and be a source of variability between studies. The
identiﬁcation of possible confounders and bias is complicated, espe-
cially given the retrospective approach used in most of the studies re-
viewed here.
It must be taken into account that the donors and their organs are
subjected to a speciﬁc selection process and it is expected that the
proportion of organs that are not accepted for transplantation will be
higher among older donors. For example, the Corneal Donor Study did
not use corneas with an endothelial cell density lower than 2300 cells/
mm2, despite the fact that ECD decreases with age (Gal et al., 2008). A
study by Potapov et al. also reported the use of< 10% of the hearts
from donors older than 63 years of age compared to a 60% utilization
rate in younger donors (Potapov et al., 1999). Consequently, the dys-
functional status of the organs transplanted will not mirror that of the
general population, with the proportion of grafts from older donors
underestimating the real level of deterioration of that age group. This
can be an advantage for a model trying to infer information about the
aging rate or the functional deterioration in healthy subjects with age,
as it would exclude those organs that are in worse condition, leaving a
more healthy and homogeneous population of grafts in which more
subtle diﬀerences could express themselves. However, this selection
process can be an important source of variability between studies. Apart
from being one of the main acceptance criteria itself, the age of the
donor impacts other criteria used to assess the validity of the organs for
use in transplantation and, if this quality control process is relatively
more restrictive for some organs than for others, the respective out-
comes would be less comparable. The same can be applicable to dif-
ferent studies for the same organ type, since the acceptance criteria in
this respect can also vary between diﬀerent countries and centers. For
example, in 2009 in the United States 11.4% of all donors were 60 to
70 years old and 4.4% were older than 70, while the respective per-
centages for the same year in Spain were 19.5% and 25.4% (Halldorson
and Roberts, 2013).
In addition, the relative impact that donor age has upon patient and
graft survival can be inﬂuenced by the particular complications asso-
ciated with each organ type, making the results from diﬀerent organs
less comparable for holistic analyses across multiple diﬀerent organ
types. For example, pancreas transplantation is known to have high
rates of graft failure in the early stages following transplantation due to
technical complications while, in the medium and long term, the in-
cidence and clinical signiﬁcance of CAD varies substantially between
diﬀerent organs, with patients of lung transplantation being the most
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aﬀected in this respect, with rates of BOS approaching 50 and 75% at 5
and 10 years posttransplantation, respectively (Yusen et al., 2015). By
contrast, several studies in liver transplantation have reported rates of
chronic rejection as low as 3% (Jain et al., 2001; Jacob et al., 2005;
Manousou et al., 2009), and non-hepatic complications derived from
the immunosuppressant therapy, such as malignancies and infections,
appear to be the leading causes of late mortality in these patients (Adam
et al., 2012). These diﬀerences in the incidence of chronic rejection are
in part a consequence of the diﬀerential levels of immunogenicity ex-
erted by the diﬀerent allografts, something that can also be seen in their
propensity to achieve operational tolerance (i.e. spontaneous graft ac-
ceptance following cessation of immunosuppression). In adult liver
transplantation, the rates of operational tolerance achieved after
withdrawal from immunosuppression have been estimated to be be-
tween 8% and 33%. While rare, spontaneous operational tolerance is
known to occur in patients of kidney transplantation as well, but in
heart, lung and pancreas transplantation, organs that are considered to
be more immunogenic, reports in this sense are almost non-existent
(Madariaga et al., 2015; Chandrasekharan et al., 2013).
The results we review here seem to indicate a relatively low sensi-
tivity of patient and graft survival to donor age in lung transplantation
with respect to other abdominal and thoracic organs. This result begs
the question of whether this is due to a real diﬀerence in the functional
status of the organs transplanted or due to other factors. It is known that
the outcomes of lung transplantation are particularly poor, only com-
parable to those of pancreas after PTA. For example, for adult patients
receiving an organ from a brain-dead donor in the UK between 2003
and 2005, 5-year patient survival rates for liver, heart and lung were
77%, 67% and 52% respectively, while the 5-year graft survival for
kidney, pancreas after SPK and pancreas after PTA were 84%, 72%,
50% respectively (Johnson et al., 2014). One possibility is that in a
situation of higher pressure toward graft failure and death, the eﬀect of
donor age would need to be stronger in order to noticeably aﬀect pa-
tient and graft survival outcomes.
Apart from the limitations discussed above, an additional obstacle
that this review faces is the variability between studies in key aspects
such as the outcome measured (overall graft survival, death censored
graft survival and patient survival), follow-up time (short-, medium-
and long-term analyses), year of transplantation (which fails to take
into account the continuous improvements of postoperative outcomes
seen over the years as a consequence of advances in transplant surgical
techniques, organ preservation, postoperative care and im-
munosuppressive therapy) and other confounding factors that diﬀer (in
terms of the number and type of confounding factors analyzed) from
procedure to procedure and from analysis to analysis. Other particu-
larities of the studies presented here also limit the potential of this
systematic review to infer information about organ and organismal
aging. Only a few studies took into account the age of the recipients
together with the age of the donors in their analysis, therefore lacking
results on the eﬀect of donor and recipient age in the diﬀerent donor-
recipient age combinations. Likewise, the inclusion of more post-
transplantational data informing of the physiological or histological
status of the transplanted organs over time or the use of longer follow-
up times in some of the studies would have enhanced their value from
an aging research perspective.
Despite the numerous limitations and diﬃculties of our approach,
with the currently available and continuously increasing vast amount of
data from organ transplantation, more tailored experimental designs
could be implemented in order to minimize or overcome some of these
limitations and exploit the big potential that these data have in aging
research. Some limitations, however, seem particularly diﬃcult to solve
even with more tailored experiments. For example, in our attempt to
infer diﬀerential aging rates between organ types based on the eﬀect of
the age of the donor in the outcomes, we ﬁnd that the particular set of
posttransplantation complications and course of the outcomes associate
with each organ type represents an unsolvable obstacle for this
endeavor at the moment.
3.2. Conclusion & future research directions
The results from organ transplantation possibly reﬂect the func-
tional decline that diﬀerent tissues and organs undergo with age.
Despite the limitations inherent in reviewing results from studies that
analyze patient and graft survival outcomes in transplants and the
particular limitations that the studies included in this review may have
(see Section 3.1), the results presented here show that for each organ
type, patterns are found with respect to the age of the donor at which its
negative eﬀect upon patient and graft survival outcomes becomes sig-
niﬁcant. However, knowing how much this observed threshold corre-
lates with the dysfunctional status or the aging in each organ type en-
ough to make comparisons between them is a more complex approach
that is unlikely to succeed given the particular complications of each
organ transplantation type.
At present, the data from human organ transplantation represents a
unique and valuable resource in biogerontology that with appropriate
experimental design could help us to gain a better understanding of
some of the processes involved in organ and organismal aging.
Breakthrough advances will be needed, however, to overcome the long
term immunological consequences of receiving an allograft, either in
the form of chronic rejections or as complications derived from gen-
erally lifelong immunosuppressant therapy, which together are the
main limitations to long term survival and currently an unavoidable
source of variability between organs types. In this sense, new strategies
for the induction of tolerance, which are already showing positive re-
sults in liver and kidney human transplantations and limited success in
heart and lung transplants in animal models (Kawai et al., 2014), have
the potential to signiﬁcantly reduce this obstacle, increasing the sur-
vival rates of grafts and patients and normalizing the course of patient
outcomes between the diﬀerent organ transplantation types, thereby
creating a more appropriate landscape for their comparison.
The successful implementation of therapies for the induction of
tolerance in the diﬀerent organs would also lead to cases of organs with
a total age that exceeds that of the known natural limits of human
longevity, especially if the reuse of transplanted grafts becomes a more
regular practice. Without having to wait for this optimistic scenario to
arrive, the data currently available allows predicting that, among the
vascularized organs, some cases could eventually appear in the current
transplantation era. Probably one of the most extreme cases reported to
date is that of a liver from a 93 years old donor transplanted into a
19 year old recipient, who seven years later was still alive and without
major complications (Tolan et al., 2016). In corneal transplantation, the
more extended use of transplants from very old donors and the superior
outcomes made in this arena suggest that this limit is already being
approached. Among the records of the Danish Cornea Bank, Visby et al.
(2014) identiﬁed 88 recipients with corneas with a total age of between
100 and 118 years, with the oldest one still functioning by the time of
their study in a 57-year-old woman.
Finally, in animal models, the possibility of performing consecutive
transplantations of organs between syngeneic individuals oﬀers the
possibility of following the aging of individual organs without the im-
munological derived problems and without the limitations imposed by
the lifespan of the organism. Harrison (1973) performed serial trans-
plantation of bone marrow across successive generations of mice, ex-
ecuting a total of four serial transplants across 36months, and de-
monstrated that the bone marrow remained functional throughout its
serial transplantation, and most notably, retained its functionality past
the maximum lifespan of its initial donor (Harrison, 1973). Lee et al.
serially transplanted pancreaticoduodenal and single kidney grafts be-
tween syngeneic Lewis rats, obtaining pancreaticoduodenal grafts of up
to 42month and kidney grafts of up to 32months after, respectively, 5
and 3 rounds of consecutive old to young transplantation, which is
substantially higher than the average life expectancy of 24months of
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these animals (Lee et al., 1997, 1999). These results may be explained
by systemic factors. Indeed, heterochronic parabiosis studies have re-
vealed a number of rejuvenating eﬀects resulting from heterochronic
parabiosis in murine model organisms (Conboy et al., 2013). Together
with evidence of hypothalamic programming of systemic aging (Zhang
et al., 2013), these results show that improvements of organs trans-
planted from the old to the young can occur due to systemic factors, and
that the abovementioned possibility of transplanted organs surpassing
human longevity is plausible.
In conclusion, using data from organ transplants is a largely un-
explored approach in aging research that could provide a powerful
platform for deriving novel biogerontological data and insights.
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